Immunovant, Inc. (IMVT) reported fourth-quarter fiscal 2025 net loss of 64 cents per share, narrower than the Zacks Consensus Estimate of a loss of 72 cents. The reported figure is wider than the year-ago quarter's loss of 52 cents per share.Currently, Immunovant does not have any approved products in its portfolio. As a result, it has yet to generate revenues.The stock gained 5.6% following the better-than-expected earnings results. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Year ...